Market revenue in 2023 | USD 72.2 million |
Market revenue in 2030 | USD 110.9 million |
Growth rate | 6.3% (CAGR from 2023 to 2030) |
Largest segment | Crohn's disease |
Fastest growing segment | Ulcerative Colitis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Crohn's Disease, Ulcerative Colitis |
Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 55.96% in 2023. Horizon Databook has segmented the Saudi Arabia inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
With low local output of branded drugs compared to generic products, Saudi Arabia has the largest pharmaceutical market in the Middle East and African region. Moreover, the country is witnessing an increased incidence of IBD.
According to Karger International, incidence of IBD in Arab countries is high. Patients with IBD from Arab countries may present different characteristics as compared to people in European countries. In addition, favorable regulatory regulations to foster IBD care in the kingdom are expected to drive the market.
For instance, in December 2022, Takeda and the Saudi Gastroenterology Association partnered to advance IBD care in the country. This partnership aimed at raising awareness about IBD and advance capabilities & knowledge across Saudi’s healthcare sector.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account